The study also found that tumor progression of an anti-PD-1-resistant head and neck squamous cell carcinoma (HNSCC) model can be suppressed by combinatorial treatment of an EZH2 inhibitor and anti-PD-1. This evidence concerns the gene EZH2 and head and neck squamous cell carcinoma.